These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17539749)

  • 41. Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.
    Cornel EB
    Eur Urol; 2007 Jul; 52(1):286-7; author reply 287. PubMed ID: 17434252
    [No Abstract]   [Full Text] [Related]  

  • 42. Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin.
    Müller-Arteaga C; Batista-Miranda JE; Zubiaur Libano C; El Khoury Moreno R; Morales Solchaga G; Casas Nebra J; Leva Vallejo M; Gonzalez Garcia O; Errando-Smet C; Arlandis-Guzman S
    Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):143-150. PubMed ID: 30470585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study.
    Kay GG; Staskin DR; MacDiarmid S; McIlwain M; Dahl NV
    Clin Drug Investig; 2012 Oct; 32(10):707-14. PubMed ID: 22909146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of combined oral-intravesical oxybutynin hydrochloride treatment for patients with overactive detrusors and indwelling urethral catheters.
    Ersoz M; Yildiz N; Akyuz M; Koseoglu F
    Rehabil Nurs; 2010; 35(2):80-6. PubMed ID: 20306617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
    Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
    Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
    Oki T; Toma-Okura A; Yamada S
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
    Staskin DR; Rosenberg MT; Dahl NV; Polishuk PV; Zinner NR
    Int J Clin Pract; 2008 Jan; 62(1):27-38. PubMed ID: 17983434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topical oxybutynin chloride for relaxation of dysfunctional bladders.
    Brendler CB; Radebaugh LC; Mohler JL
    J Urol; 1989 Jun; 141(6):1350-2. PubMed ID: 2724432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity.
    Asimakopoulos AD; Cerruto MA; Del Popolo G; La Martina M; Artibani W; Carone R; Finazzi-Agrò E
    Urol Int; 2012; 89(3):259-69. PubMed ID: 22777274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of hyperhidrosis with oxybutynin.
    Schollhammer M; Misery L
    Arch Dermatol; 2007 Apr; 143(4):544-5. PubMed ID: 17438194
    [No Abstract]   [Full Text] [Related]  

  • 54. The use of intravesical oxybutynin chloride in children with neurogenic bladder.
    Greenfield SP; Fera M
    J Urol; 1991 Aug; 146(2 ( Pt 2)):532-4. PubMed ID: 1861294
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
    BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial.
    Schröder A; Albrecht U; Schnitker J; Reitz A; Stein R
    Neurourol Urodyn; 2016 Jun; 35(5):582-8. PubMed ID: 25754454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
    Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
    Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New transdermal bioadhesive film containing oxybutynin: In vitro permeation across rabbit ear skin.
    Nicoli S; Penna E; Padula C; Colombo P; Santi P
    Int J Pharm; 2006 Nov; 325(1-2):2-7. PubMed ID: 16860952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder].
    Sonoda T; Sakurai T; Yamada K; Mizutani S; Tsujimoto Y; Ogawa T
    Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
    Gittelman M; Weiss H; Seidman L
    J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.